Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Glucotrack, Inc.
organization6 mentionslast seen Oct 28, 2026
A biopharmaceutical company focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system.
Relationships 13
- Glucotrack, Inc.employsErik Emerson99% confidence5 sources
- Glucotrack, Inc.ownsGlucotrack Technologies, Inc.99% confidence3 sources
- Glucotrack, Inc.developsGlucotrack CBGM99% confidence2 sources
- Glucotrack, Inc.acquiresLōkahi Therapeutics98% confidence1 source
- Glucotrack, Inc.funded byGlucotrack October 2026 convertible note financing96% confidence1 source
- Glucotrack, Inc.funded byGlucotrack September 2026 Convertible Notes Financing95% confidence1 source
- Glucotrack, Inc.funded byGlucotrack registered direct offering September 202695% confidence1 source
- Dawson James Securities, Inc.suppliesGlucotrack, Inc.92% confidence1 source
- Glucotrack, Inc.ownsLōkahi Therapeutics92% confidence1 source
- Glucotrack, Inc.commercializesGlucotrack CBGM90% confidence1 source
- Glucotrack, Inc.conforms toNasdaq Listing Rule 5635(d)90% confidence1 source
- Dawson James Securities, Inc.suppliesGlucotrack, Inc.85% confidence1 source
- Glucotrack, Inc.invests inWhite Lion Capital, LLC85% confidence1 source
Relationship
Glucotrack, Inc.employsErik Emerson
99% confidence5 supporting mentions
Either name opens that entity’s relationships.
Sources 5
- filingSEC EDGAROct 28, 2026Glucotrack, Inc. 8-K: Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Erik Emerson Name: Erik Emerson Title: Chief Executive Officer
- filingSEC EDGAROct 22, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Name: Erik Emerson Title: Chief Executive Officer
- filingSEC EDGAROct 19, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
Erik Emerson Title: Chief Executive Officer
- filingSEC EDGARSep 24, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Erik Emerson, Name: Erik Emerson, Title: Chief Executive Officer
- filingSEC EDGARSep 11, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Erik Emerson Title: Chief Executive Officer